PTC spikes on interim pivotal data for oral SMA candidate

PTC Therapeutics Inc. (NASDAQ:PTCT) gained $10.33 (28%) to $47.88 after reporting updated interim data from part 1 of the pivotal Phase II/III FIREFISH trial showing that oral risdiplam (RG7916) improved motor development scores in infants with spinal muscular atrophy (SMA)

Read the full 401 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE